



**RESISTANCE TO RECOMBINANT HUMAN
ERYTHROPOIETIN THERAPY IN HAEMODIALYSIS
PATIENTS – FOCUS ON INFLAMMATORY CYTOKINES,
LEUKOCYTE ACTIVATION, IRON STATUS AND
ERYTHROCYTE DAMAGE**

Elísio Costa^{1,2,*}, Luís Belo^{2,3}, Alexandre Quintanilha^{2,4}, Alice Santos-Silva^{2,3}

¹Instituto de Ciências da Saúde da Universidade Católica Portuguesa

²Instituto de Biologia Molecular e Celular da Universidade do Porto

³Faculdade de Farmácia da Universidade do Porto

⁴Instituto de Ciências Biomédicas Abel Salazar

<p>Keywords</p> <p>Haemodialysis, Resistance to rhEPO therapy, Erythropoietin, Inflammation, leukocyte Activation, Iron Status, Erythrocyte Damage</p>	<p>Abstract</p> <p>Anaemia is a common complication in haemodialysis patients. This condition is associated to a decreased bone marrow production of erythrocytes, mainly due to the inability of the failing kidneys to secrete erythropoietin (EPO). The introduction of recombinant human EPO (rhEPO) therapy led to a significant reduction in anaemia and improved patients' quality of life. However, there is a marked variability in the sensitivity to rhEPO, with up to 10-fold variability in dose requirements to achieve correction of anaemia. Approximately 5-10% of the patients show a marked resistance to rhEPO therapy. rhEPO resistance is associated to an increased morbidity and mortality of haemodialysis patients. In this paper a revision of the mechanisms underlying resistance to rhEPO therapy will be performed, with particular emphasis on inflammatory cytokines, leukocyte activation, iron status, and erythrocyte damage.</p> <p>© 2009 Journal of Nephrology and Renal Transplantation. All rights reserved</p>
---	---

1. Introduction

Anaemia is a common complication that contributes to the burden of haemodialysis (HD) patients. It has also a negative impact on cardiovascular

* Corresponding author. Instituto de Ciências da Saúde, Universidade Católica Portuguesa, Rua Dr. António Bernardino de Almeida 4200-072 Porto, Portugal;

Email: elisio_costa@hotmail.com ; ecosta@ics.porto.ucp.pt

system, cognitive function, exercise capacity and quality of life, resulting in a significant morbidity and mortality in these patients. The introduction of rhEPO therapy in the early 1990s for treatment of anaemia of HD patients has led to a significant reduction in anaemia and to an improvement in patients' quality of life (1-4). There is, however, a marked variability in the sensitivity to rhEPO, with up to 10-fold variability in dose requirements to achieve correction of the anaemia. Furthermore, around 5-10% of the patients show a marked resistance to rhEPO therapy (2,4-6). The European Best Practice Guidelines define "resistance to rhEPO therapy" as a failure to achieve target haemoglobin levels (between 11 and 12 g/dL) with maintained doses of rhEPO higher than 300 IU/Kg/week of epoetin or of higher doses than 1.5 µg/Kg/week of darbopoietin-alfa (7).

The reasons for this variability in rhEPO response are unclear (4, 8-12). There are a lot of conditions reported as associated with rhEPO resistance, namely, inflammation, oxidative stress and iron deficiency, as major causes (4, 8-14), and blood loss, hyperparathyroidism, aluminium toxicity and vitamin B12 or folate deficiency, as minor causes. However, exclusion of these factors does not eliminate the marked variability in sensitivity to rhEPO (15).

In this paper a revision of the mechanisms of resistance to rhEPO therapy will be performed, with particular emphasis on inflammatory cytokines, leukocyte activation, iron status, and erythrocyte damage.

2. Inflammatory cytokines

Inflammation is the physiological response to a variety of noxious stimuli such as tissue injury caused by infection or physical damage. It is a complex process that involves the participation of several cells and molecules, and may present different intensities and durations.

Inflammation usually refers to a localised process. However, if the noxious stimulus is severe enough, distant systemic changes may also occur, and these changes are referred as "acute phase response", which is accompanied by signs and symptoms such as fever, anorexia, and somnolence. This acute phase response may include neuroendocrine, metabolic and haematopoietic changes, as well as changes in non-protein plasma constituents (16). The haematopoietic response includes leukocytosis and leukocyte activation, thrombocytosis, and anaemia secondary to erythrocyte damage and/or decreased erythropoiesis (17).

Inflammatory stimuli induces the release of cytokines, including tumour necrosis factor (TNF)- α , interleukin (IL) -1, IL-6, and interferon (IFN)- γ , which may be produced by several cells, including leukocytes, fibroblasts and

endothelial cells (18). This release of cytokines causes many systemic changes, including increased synthesis and release of positive acute-phase proteins, such as C-reactive protein (CRP) and fibrinogen, as well as the suppression of negative acute-phase proteins, such as albumin and transferrin (4,11,19).

The causes for the inflammatory response in HD patients are not well clarified. There are several potential sources, including bacterial contamination of the dialyser, incompatibility with the dialyser membrane and infection of the vascular access. However, the dialysis procedure may only be partially responsible for the inflammatory response, because even patients with renal insufficiency who are not yet on dialysis present raised inflammatory markers, which rise further after starting regular HD treatment, suggesting that the disease per se triggers an inflammatory response (6,13,15).

Along an inflammatory response, the iron from the erythropoiesis traffic is mobilised to storage sites within the reticuloendothelial system, inhibiting erythroid progenitor proliferation and differentiation, and blunting, therefore, the response to erythropoietin (EPO) (endogenous and/or exogenous). An erythropoiesis-suppressing effect has been also attributed to increased activity of pro-inflammatory cytokines reported in this inflammatory condition, and this relationship has been proposed as a potential factor associated to rhEPO therapy resistance (6,13,15,20). Actually, it was reported that pro-inflammatory cytokines, such as IL-1, IL-2, IL-4, IL-6, TNF- α and INF- γ diminish BFU-E and CFU-E cells, resulting in suppression of erythropoiesis (5,21,22). Moreover, it was reported (5) that serum derived from haemodialysed patients suppresses erythroid colony-forming response to EPO, in a manner that can be inhibited by antibodies against TNF- α and INF- γ . These data suggest a key role in the rhEPO response for these inflammatory mediators (8,11,23,24).

Recently, our group demonstrated an activation of T-cells and an enhanced ability of these cells to produce Th1 related cytokines (IL-2, INF- γ and TNF- α) after short term in vitro stimulation, although these cytokines were undetectable in serum. This increased capacity to produce Th1 cytokines could justify, at least in part, the anaemia found in HD patients. However, this enhanced capacity to produce cytokines was not associated to the refractoriness to rhEPO therapy, as previously described in non-responders HD patients (11). We also demonstrated that non-responders patients presented higher C-reactive protein (CRP) and lower albumin serum levels as compared to responders (25), suggesting a relationship between resistance to rhEPO therapy and the inflammatory response (Table I).

Table 10- Inflammatory markers among HD patients (responders and non-responders to rhEPO therapy).

	rhEPO responders	rhEPO non-responders
White cell counts	N	N
Neutrophils counts	↑	↑
Albumin serum levels	N	↓
CRP serum levels	↑	↑↑
IL-6 serum levels	↑	↑↑
Soluble IL-2 receptor serum levels	↑	↑
Elastase plasma levels	↑	↑↑

N: normal values when compared with healthy controls; ↑: increase values when compared with healthy controls; ↓: decrease values when compared with healthy controls; ↑↑ increase values when compared with responders patients. Adapted from references 25 and 40.

3. Leukocyte activation

Leukocytosis and recruitment of circulating leukocytes into the affected areas are hallmarks of inflammation. Leukocytes are chemo-attracted to inflammatory regions and their transmigration from blood to the injured tissue is primarily mediated by the expression of cell-adhesion molecules in the endothelium, which interact with surface receptors on leukocytes (26,27). This leukocyte-endothelial interaction is regulated by a cascade of molecular steps that correspond to the morphological changes that accompany adhesion. At the inflammatory site, leukocytes release their granulation products and may exert their phagocytic capacities.

In acute inflammation, the leukocyte infiltration is predominantly of neutrophils, whereas in chronic inflammation a mononuclear cell infiltration (predominantly macrophages and lymphocytes) is observed. Although leukocyte-endothelial cell interaction is important for leukocyte extravasation and trafficking in physiological situations, there is increasing evidence that altered leukocyte-endothelial interactions are implicated in the pathogenesis of diseases associated with inflammation, possibly by damaging the endothelium or altering endothelial function (28,29).

Leukocytosis is essential as the primary host defence, and neutrophils, the major leukocyte population of blood in adults, play a primordial role. It is well known that neutrophils have mechanisms that are used to destroy invading microorganisms. These cells use an extraordinary array of oxygen-dependent and oxygen-independent microbicidal weapons to destroy and remove infectious agents (30). Oxygen-dependent mechanisms involve the production of reactive

oxygen species (ROS), which can be microbicidal (31), and lead to the development of oxidative stress. Oxygen-independent mechanisms include chemotaxis, phagocytosis and degranulation. The generation of microbicidal oxidants by neutrophils results from the activation of a multiprotein enzyme complex known as the reduced nicotinamide adenine dinucleotide phosphate oxidase, which catalyzes the formation of superoxide anion ($O_2^{\cdot-}$). Activated neutrophils also undergo degranulation, with the release of several components, namely, proteases (such as elastase) and cationic proteins (such as lactoferrin).

Elastase is a member of the chymotrypsin superfamily of serine proteinases, expressed in monocytes and mast cells, but mainly expressed by neutrophils, where it is compartmentalized in the primary azurophil granules. The intracellular function of this enzyme is the degradation of foreign microorganisms that are phagocytosed by the neutrophil (32). Elastase can also degrade local extracellular matrix proteins (such as elastin), remodel damaged tissue, and facilitate neutrophil migration into or through tissues. Moreover, elastase also modulates cytokine expression at epithelial and endothelial surfaces, up-regulating the production of cytokines, such as IL-6, IL-8, transforming growth factor β (TGF- β) and granulocyte-macrophage colony-stimulating factor (GM-CSF); it also promotes the degradation of cytokines, such as IL-1, TNF- α and IL-2. There is evidence in literature that high levels of elastase are one of the major pathological factors in the development of several chronic inflammatory lung conditions (33).

Plasma lactoferrin is predominantly neutrophil derived and its presence in the specific granules is often used to identify these types of granules. Lactoferrin is also found in other granules, in the tertiary granules, though in lower concentrations (34-37). Lactoferrin is a multifunctional iron glycoprotein, which is known to exert a broad-spectrum primary defence activity against bacteria, fungi, protozoa and viruses. It can bind to large amounts of free iron. The iron bound to lactoferrin is taken up by activated macrophages, which express specific lactoferrin receptors. During inflammation, this causes iron deprivation of the erythroid precursors, which fail to express lactoferrin receptors (38). Other mechanisms in which lactoferrin is implicated include a growth regulatory function in normal cells, coagulation, and perhaps cellular adhesion modulation (39).

There are no considerable data concerning to the correlation between leukocyte activation and resistance to rhEPO therapy, particularly to the neutrophil activation. We recently found that patients under HD, particularly non-responders patients, present higher elastase plasma levels, compared to

healthy controls (40). Moreover, we demonstrated neutrophil activation, triggered by HD procedure. However, the HD procedure does not explain the higher elastase levels found in non-responders patients. Moreover, we found statistically significant positive correlations between elastase levels and CRP, suggesting that the rise in elastase levels is part of the inflammatory process found in HD patients, being particularly enhanced in non-responders. The statistically significant correlation that we also found between elastase levels and weekly rhEPO doses also corroborate this hypothesis; in fact, non-responders to rhEPO therapy patients requiring higher weekly rhEPO doses to achieve target hemoglobin levels, are also associated with an increased inflammatory process.

The increase plasma levels of elastase found in HD patients can be associated to alterations in erythrocyte membrane proteins, which could decrease erythrocyte half life in HD patients, particularly in non-responders, and consequently increase the degree of anaemia in these patients.

Table II - Iron status markers among HD patients (responders and non-responders to rhEPO therapy).

	rhEPO responders	rhEPO non-responders
Haemoglobin concentration	↑	↓↓
Mean cell haemoglobin	N	↓
Mean cell haemoglobin concentration	N	↓
RDW (red cell distribution width)	↑	↑↑
Transferrin saturation	N	N
Ferritin serum levels	↑	↑
Transferrin serum levels	↓	↓
s-TfR serum levels	N	↑
Prohepcidin serum levels	↑	↑

N: normal values when compared with healthy controls; ↑: increase values when compared with healthy controls; ↓: decrease values when compared with healthy controls; ↑↑ increase values when compared with responders patients; ↓↓ decrease values when compared with responders patients. Adapted from reference 61.

4. Iron status

Iron is an essential trace element that is required for growth and development of living organisms, but excess of free iron is toxic for the cell (41-43). Mammals lack a regulatory pathway for iron excretion, and iron balance is maintained by the tight regulation of iron absorption from the intestine (42,44). The intestinal

iron absorption is regulated by the level of body iron stores and by the amount of iron needed for erythropoiesis (41,42,44,45).

In HD patients, iron absorption is similar to that found in healthy individuals; however, when under rhEPO therapy, the absorption of iron increases as much as 5 times (46). This increased iron absorption is not sufficient to compensate for the iron lost during the HD procedure, and with the frequent blood draws performed on these patients. For this reason, intravenous iron administration has become a standard therapy for most patients receiving rhEPO. To avoid iron overload, with potentially harmful consequences, there is a need to monitor iron therapy by performing regular blood tests reflecting body's iron stores.

Recently, a complex regulatory network that governs iron traffic emerged, and points to hepcidin as a major evolutionary conserved regulator of iron distribution (47-49). This small hormone produced by the mammalian liver has been proposed as a central mediator of dietary iron absorption. High levels of hepcidin were found to be associated with a decrease in both iron uptake from the small intestine and in iron release from macrophages; a decreased placental iron transport was also observed (50).

The synthesis of hepcidin is stimulated by inflammation and iron overload. The *in vitro* stimulation of fresh human hepatocytes by pro-inflammatory IL-6 showed strong induction of hepcidin mRNA, indicating that this cytokine may be an important mediator of hepcidin induction in inflammation (51-57). It is synthesized as preprohepcidin, a protein with 84 amino acids. This peptide is cleaved leading to prohepcidin with 60 aminoacids, which is further processed giving rise to the 25 aminoacids protein, hepcidin (51,52).

Hepcidin was reported to bind to the transmembrane iron exporter ferroportin, which is present on macrophages, on the basolateral site of enterocytes, and also on hepatocytes. It has been demonstrated *in vitro* that hepcidin induces the internalization and degradation of ferroportin, a crucial protein for cellular iron export (53). By diminishing the effective number of iron exporters on the membrane of enterocytes and of macrophages, hepcidin suppresses iron uptake and release, respectively. This is the phenotype of ferroportin disease, where iron accumulation is observed mainly in macrophages and often combined with anaemia (54).

This increased hepcidin expression during inflammation explains sequestration of iron in the macrophages and inhibition of intestinal iron absorption, the two hallmarks of the anaemia of inflammation, which is normocytic or microcytic iron-refractory (47,50,52). This decreased availability in iron may be a host defence mechanism against invading microorganisms.

The biological importance of the precursor molecule of hepcidin, named prohepcidin, in regulating iron metabolism, is still undetermined. However, there is some evidence that prohepcidin levels are a reliable indicator of hepcidin levels and activity (50,52,58,59).

Hepcidin synthesis is regulated by inflammation, a common finding in HD patients. Thus, increased levels of prohepcidin have been reported in HD patients (50,52,58-60).

We recently demonstrated that HD patients non-responders to rhEPO therapy present a mild to moderate anaemia, even with the administration of higher rhEPO doses (61). This anaemia is hypochromic [decreased mean cell haemoglobin (MCH) and mean cell haemoglobin concentration (MCHC)], and is associated with a more accentuated anisocytosis than in responder patients. Considering that all patients, in our study, were under iron and folate prophylactic therapies, and, that iron status and vitamin B12 serum levels were normal, these changes could not be attributable to a deficiency in these erythropoietic nutrients. Actually, the HD patients non-responders to rhEPO therapy seem to present a “functional” iron deficiency, characterized by the presence of adequate iron stores as defined by conventional criteria, but apparently with an inability to sufficiently mobilize iron to adequately support erythropoiesis. In fact, no statistically significant differences were found in serum iron status markers between the groups of patients (responders and non-responders), except for the soluble transferrin receptor (s-TfR), which was statistically significant higher among non-responders (Table II). This “functional” iron deficiency is reflected by a decrease in MCH and in MCHC, and by a more accentuated anisocytosis (high RDW) in non-responders patients. Furthermore, the inverse correlation that we have found between CRP and mean cell volume, MCH, serum iron and transferrin saturation, are in agreement with the observations that the chronic inflammation enhanced in non-responders, may lead to trapping of iron within the macrophages and to a reduction in serum iron levels. Additionally, HD patients non-responders to rhEPO therapy presented lower prohepcidin serum levels when compared with responders. As previously referred, hepcidin is up-regulated by inflammation; however, on the other hand EPO downregulates liver hepcidin expression (62). As non-responders patients were treated with much higher doses of rhEPO compared with responders, the lower prohepcidin levels found in those patients could be explained by this mechanism.

5. Erythrocyte damage

The erythrocyte, presenting a limited biosynthesis capacity, suffers and accumulates physical and/or chemical changes, which become more pronounced with cell aging, and whenever an unusual physical or chemical stress develops (63).

The erythrocyte membrane is a complex structure comprising a lipidic bilayer, integral proteins and the skeleton. Spectrin is the major protein of the cytoskeleton, and, therefore, the major responsible for erythrocyte shape, integrity and deformability. It links the cytoskeleton to the lipid bilayer, by vertical protein interactions with the transmembrane proteins, band 3 and glycophorin A (64). In the vertical protein interaction of spectrin with band 3 are also involved ankyrin (also known as band 2.1) and protein 4.2. A normal linkage of spectrin with the other proteins of the cytoskeleton assures normal horizontal protein interactions.

Erythrocytes are physically stressed during the HD process, and metabolically stressed by the unfavourable plasmatic environment, due to metabolite accumulation, and by the high rate of haemoglobin autoxidation, due to the increase in haemoglobin turnover, a physiologic compensation mechanism triggered in case of anaemia (64,65). The erythrocytes are, therefore, continuously challenged to sustain haemoglobin in its reduced functional form, as well as to maintain the integrity and deformability of the membrane.

When haemoglobin is denatured, it links to the cytoplasmic pole of band 3, triggering its aggregation and leading to the formation of strictly lipidic portions of the membrane, poorly linked to the cytoskeleton. These cells are probably more prone to undergo vesiculation (loss of poorly linked membrane portions) whenever they have to circulate through the haemodialysis membranes or the microvasculature. Vesiculation may, therefore, lead to modifications in the erythrocyte membrane of HD patients (66,67).

Erythrocytes that develop intracellular defects earlier during their life span are removed prematurely from circulation (68,69). The removal of senescent or damaged erythrocytes seems to involve the development of a senescent neoantigen on the plasma membrane surface, marking the cell for death. This neoantigen is immunologically related to band 3 (70). The deterioration of the erythrocyte metabolism and/or of its antioxidant defences may lead to the development of oxidative stress within the cell, allowing oxidation and linkage of haemoglobin to the cytoplasmatic domain of band 3, promoting its aggregation,

the binding of natural antibody 3 autoantibodies and complement activation, marking the erythrocyte for death.

The band 3 profile [high molecular weight aggregates (HMWAg), band 3 monomer and proteolytic fragments (Pfrag)], differs among younger, damaged and/or senescent erythrocytes. Older and damaged erythrocytes present with higher HMWAg and lower Pfrag. Younger erythrocytes show reduced HMWAg and higher Pfrag (69). Moreover, several diseases, known as inflammatory conditions, presented abnormal band 3 profiles, suggestive of oxidative stress development (68,69,71).

HD patients present a reduction in erythrocyte membrane spectrin, though without statistically significance, was found in non-responders patients. This spectrin deficiency was accompanied by the production of hypochromic and anisocytic erythrocytes, and this anisocytosis could reflect an even more enhanced change in membrane protein interactions in non-responders (73,74). Non-responders patients also showed a decrease in Pfrag and in Pfrag/band 3 monomer ratio (Fig. 1) and a trend to higher values of membrane bound haemoglobin (75), suggesting that they present a higher erythrocyte damage that may result from an even more adverse plasmatic microenvironment. When studying the differences in membrane protein composition before and after the haemodialysis procedure, we found that this spectrin reduction was enhanced in the non-responder group (76); moreover, we observed that this could be associated to an enhanced inflammation process and/or to the interaction with proteases released by neutrophils as we also found significant rise in elastase, product of leukocyte activation.

6. Conclusions

Although the etiology of resistance to rhEPO therapy is still unknown, inflammation seems to have an important role in its pathophysiology. Resistance to rhEPO therapy is also associated with “functional” iron deficiency, higher elastase plasma levels, and alterations in erythrocyte membrane protein structure and in band 3 profile.




Figure 6 - Illustration of two band 3 profiles. C: control; P: HD patient; HMW Ag: high molecular weight aggregates; Pfrag: proteolytic fragments.

The exact origins of the inflammatory process remain unclear. We speculate that the release of elastase during the HD procedure could have an important role in amplifying the inflammatory process in HD patients, particularly in non-responders (Fig 2). Furthermore, this elastase release could also have an important role in the alterations found in erythrocyte membrane protein structure and in band 3 profile, further contributing to worsening of anaemia (Fig 2). The inflammatory process, the rhEPO doses administered and the lactoferrin release during haemodialysis could have an important role in iron uptake from the small intestine, in the release of iron from macrophages and, finally, in the availability of iron for erythropoiesis..

Further studies are needed to understand the rise in inflammation with the associated need in higher doses of rhEPO and reduced iron availability. It will be also important to clarify the mechanism of lymphocyte loss, by studying the role of IL-7 levels and/or the peripheral lymphocyte apoptosis; the effect of higher levels of elastase in the inflammatory process, and in the alterations in erythrocyte membrane protein composition and in band 3 profile. Of great importance would be also the development of animal studies, by using a rat

model of chronic renal failure, as some histological and molecular studies, cannot be performed in humans, such as the erythropoietic and renal studies.




Figure 7 - Potential mechanisms involved in the pathophysiology of resistance to rhEPO therapy. Black lines represents responders patients and red lines non-responders patients; (+) represents activation and (-) inhibition.

REFERENCES

- [1] Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity – the experience of the Lombardy dialysis registry. *Nephrol Dial Transplant* 1998 ;13:1642-44.
- [2] Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. *Nephrol Dial Transplant* 2001;16:224-7.
- [3] Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ. Anaemia in haemodialysis patients of five European countries: association with

- morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant* 2004; 19:121-32.
- [4] Smrzova J, Balla J, Bárány P. Inflammation and resistance to erythropoiesis-stimulating agents--what do we know and what needs to be clarified? *Nephrol Dial Transplant* 2005;20 (Suppl 8):viii2-7.
- [5] Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. *Nephrol Dial Transplant* 2002;17(Suppl 11):39-43.
- [6] Schindler R, Senf R, Frei U. Influencing the inflammatory response of hemodialysis patients by cytokine elimination using large-pore membranes. *Nephrol Dial Transplant* 2002;17:17-19
- [7] Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. *Nephrol Dial Transplant* 2004;19 [Suppl 2]: ii1-ii47.
- [8] Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy morbidity and mortality in end-stage renal disease. *Am J Kidney Dis* 1996;28:53-61.
- [9] Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW. Oxidative stress and inflammation in hemodialysis patients. *Am J Kidney Diseases* 2001;38:1408-13.
- [10] Drueke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. *Nephrol Dial Transplant* 2002;17(suppl 5):28-31.
- [11] Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN- γ , TNF- α , IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. *J Am Soc Nephrol* 2003;14:1776-84.
- [12] Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? *Seminars in Dialysis* 2004;17:449-454.
- [13] Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis* 1999;33:63-72.
- [14] Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. *Kidney International* 2004;65:2371-9.
- [15] Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. *Nephrol Dial Transplant* 2002;17(Suppl 11):39-43.
- [16] Ceciliani F, Giordano A, Spagnolo V. The systemic reaction during inflammation: the acute-phase proteins. *Curr Pharm Des* 2002 ;9:211-23.
- [17] Trey JE, Kushner I. (1995). The acute phase response and the hematopoietic system: the role of cytokines. *Crit Rev Oncol Hematol* 21:1-18.

- [18] Kushner I, Rzewnicki D. Acute phase response, pp. 317-29. In Gallin JI, Snyderman R, Fearon DT, Haynes BF, Nathan C [eds.], *Inflammation: basic principles and clinical correlates*, 3rd ed. Lippincott Williams Wilkins, Philadelphia; 1999.
- [19] Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. *Nephrol Dial Transplant* 1995;10:607-14.
- [20] Cooper AC, Breen CP, Vyas B, Ochola J, Kemeny DM, Macdougall IC. Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production. *Nephrol Dial Transplant* 2003;18:133-40.
- [21] Means RT Jr, Krantz SB. Inhibition of human erythroid colony forming units by interferons α and β : differing mechanisms despite shared receptor. *Exp Haematol* 1996;24:204-8.
- [22] Allen DA, Breen C, Yaqoob MM, Macdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of INF- γ and TNF- α . *J Invest Med* 1999;47:204-11.
- [23] Waltzer WC, Bachvaroff RJ, Raisbeck AP, Egelanddal B, Pullis C, Shen L, Rapaport FT. Immunological monitoring in patients with end-stage renal disease. *J Clin Immunol* 1984;4:364-8.
- [24] Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. *J Am Soc Nephrol* 2002;13:204-212.
- [25] Costa E, Lima M, Alves JM, Rocha S, Rocha-Pereira P, Castro E, Miranda V, Faria MD, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. *J Clin Immunol* 2008; 28:268-275.
- [26] Muller WA. Leukocyte-endothelial cell adhesion molecules in transendothelial migration, pp. 585-592. In Gallin JI, Snyderman R, Fearon DT, Haynes BF and Nathan C [eds.], *Inflammation: basic principles and clinical correlates*, 3rd ed. Lippincott Williams Wilkins, Philadelphia; 1999.
- [27] Sullivan GW, Sarembock IJ, Linden J. The role of inflammation in vascular diseases. *J Leukoc Biol* 2000;67:591-602.
- [28] Harlan JM. (1985). Leukocyte-endothelial interactions. *Blood* 65:513-25.
- [29] Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nature Reviews Immunology* 2007 ;7: 678-89.
- [30] Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. *Lab Invest* 2000;80, 617-653.
- [31] Roos D, Van Bruggen R, Meischl C. Oxidative killing of microbes by neutrophils. *Microbes Infect* 2003;5, 1307-15.
- [32] Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. *Science* 2004;303:1532-5.

- [33] Fitch PM, Roghanian A, Howie SEM, Sallenave JM. Human neutrophil elastase inhibitors in innate and adaptive immunity. *Biochemical Society Transactions* 2006;34:279-82.
- [34] Olofsson T, Olsson I, Venge P, Elgefors B. Serum myeloperoxidase and lactoferrin in neutropenia. *Scand J Haematol* 1977 ;18:73-80.
- [35] Baynes R, Bezwoda W, Bothwell T, Khan Q, Mansoor N. The non immune inflammatory response: serial changes in plasma iron, iron binding capacity, lactoferrin, ferritin and C reactive protein. *Scan J Clin Lab Invest* 1986;46:695-704.
- [36] Halliwell B, Gutteridge JMC. The antioxidants of human extracellular fluids. *Arch Biochem Biophys* 1990;280:1-8.
- [37] Saito N, Takemori N, Hirai K, Onodera R, Watanabe S, Naiki M. Ultrastructural localization of lactoferrin in the granules other than typical secondary granules of human neutrophils. *Human Cell* 1993;6:42-8.
- [38] Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. *Nephrol Dial Transplant* 2001;16:224-7.
- [39] Levay PF, Viljoen M. Lactoferrin: a general review. *Haematologica* 1995;80:252-67.
- [40] Costa E, Rocha S, Rocha-Pereira P, Nascimento H, Castro E, Miranda V, Faria MS, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Neutrophil activation and resistance to recombinant human erythropoietin therapy in haemodialysis patients. *Am J Nephrol* 2008;28:935-940.
- [41] Arth RH. Iron metabolism in end-stage renal disease. *Seminars in Dialysis* 1999;12:224-30.
- [42] Atanasio V, Manolescu B, Stoian I. Heparin – central regulator. *Eur J Haematol* 2006;78:1-10.
- [43] Deicher R, Horl WH. New insights into the regulation of iron homeostasis. *European J Clin Invest* 2006;36:301-9.
- [44] Park CH, Valore AJ, Waring AJ, Ganz T. Heparin, a urinary antimicrobial peptide synthesized in the liver. *J Biol Chem* 2001;276:7806-10.
- [45] Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Heparin, a putative mediator of anemia of inflammation, is type II acute-phase protein. *Blood* 2003;101:2461-63.
- [46] Skikne BS, Cook JD. Effect of enhanced erythropoiesis on iron absorption. *J Lab Clin Med* 1992;120:746-51.
- [47] Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide heparin is regulated by anemia, hypoxia, and inflammation. *J Clin Invest* 2002 ;110:1037-44.
- [48] Kemma E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D. Novel urine heparin assay by mass spectrometry. *Blood* 2005;106:3268-70.

- [49] Nemeth E, Preza GC, Jun CL, Kaplan J, Waring AJ, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. *Blood* 2006;107:328-33.
- [50] Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anemia. *Gut* 2004;53:735-43.
- [51] Dallaglio G, Fleury T, Means RT. Serum hepcidin in clinical specimens. *Br J Haematol* 2003;122:996-1000.
- [52] Hsu SP, Ching CK, Chien CT, Hung KY. Plasma Prohepcidin positively correlates with haematocrit in chronic hemodialysis patients. *Blood Purif* 2006;24:311-6.
- [53] Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, Sundquist WI, Ganz T, Musci G, Kaplan J. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. *Mol Biol Cell* 2007;18:2569-78.
- [54] Njajou OT, de Jong G, Berghuis B, Vaessen N, Snijders PJ, Goossens JP, Wilson JH, Breuning MH, Oostra BA, Heutink P, Sandkuijl LA, van Duijn CM. Dominant hemochromatosis due to N144H mutation of SLC11A3: clinical and biological characteristics. *Blood Cells Mol Dis* 2002;29:439-43.
- [55] Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. *Proc Natl Acad USA* 2001;98:8160-2.
- [56] Nemeth E, Preza GC, Jun CL, Kaplan J, Waring AJ, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. *Blood* 2006;107:328-33.
- [57] Carbia-Nagashima A, Arzt E. Intracellular proteins and mechanisms involved in the control of gp130/JAK/STAT cytokine signaling. *IUBMB Life* 2004;56:83-8.
- [58] Taes YEC, Wuyts B, Boelaert JR, Vriese AS, Delanghe JR. Prohepcidin accumulates in renal insufficiency. *Clin Chem Lab Med* 2004;42:387-9.
- [59] Hsu SP, Ching CK, Chien CT, Hung KY. Plasma Prohepcidin positively correlates with haematocrit in chronic hemodialysis patients. *Blood Purif* 2006;24:311-6.
- [60] Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. *J Clin Invest* 2002 ;110:1037-44.
- [61] Costa E, Pereira BJG, Rocha-Pereira P, Rocha S, Reis F, Castro E, Teixeira F, Miranda V, Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. *Am J Nephrol* 2008;28:677-683.
- [62] Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. *Physiol Res* 2006;55:667-74.

- [63] Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant* 2004;19:121-32.
- [64] Lucchi L, Bergamini S, Botti B, Rapanà R, Ciuffreda A, Ruggiero P, Ballestri M, Tomasi A, Albertazzi A. Influence of different hemodialysis membrane on red blood cell susceptibility of oxidative stress. *Artif Organs* 2000;24:1-6.
- [65] Stoya G, Klemm A, Baumann E, Vogelsang H, Ott U, Linss W, Stein G. Determination of autofluorescence of red blood cells (RbCs) in uremic patients as a marker of oxidative damage. *Clin Nephrol* 2002;58:198-204.
- [66] Reliene R, Marini M, Zanella A, Reinhart WH, Ribeiro ML, del Giudice EM, Perrotta S, Ionoscon A, Eber S, Lutz HU. Splenectomy prolongs in vivo survival of erythrocytes differently in spectrin/ankyrin- and band 3-deficient hereditary spherocytosis. *Blood* 2002;100:2208-15.
- [67] Rocha S, Rebelo I, Costa E, Catarino C, Belo L, Castro EMB, Cabeda JM, Barbot J, Quintanilha A, Santos-Silva A. Protein deficiency balance as a predictor of clinical outcome in hereditary spherocytosis. *Eur J Haematol* 2005;74:374-80.
- [68] Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Erythrocyte damage in mild and severe psoriasis. *Br J Dermatology* 2004;150:232-44.
- [69] Santos-Silva A, Castro EMB, Teixeira NA, Guerra FC, Quintanilha A. Erythrocyte membrane band 3 profile imposed by cellular aging, by activated neutrophils and by neutrophilic elastase. *Clin Chim Acta* 1998;275: 185-96.
- [70] Kay MM, Wyant T, Goodman J. Autoantibodies to band 3 during aging and disease and aging interventions. *Ann N Y Acad Sci* 1994;719:419-47.
- [71] Belo L, Rebelo I, Castro EMB, Catarino C, Pereira-Leite L, Quintanilha A, Santos-Silva A. Band 3 as a marker of erythrocyte changes in pregnancy. *Eur J Haematol* 2002;69:145-51.
- [72] Costa E, Rocha S, Rocha-Pereira P, Castro E, Miranda V, Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Altered erythrocyte membrane protein composition in chronic kidney disease stage 5 patients under haemodialysis and recombinant human erythropoietin therapy. *Blood Purification* 2008;26:267-273.
- [73] Sevillano G, Rodríguez-Puyol M, Martos R, Duque I, Lamas S, Díez-Marques ML, Lúcio J, Rodríguez-Puyol D. Cellulose acetate membrane improves some aspects of red blood cell function in hemodialysis patients. *Nephrol Dial Transplant* 1990;5:497-9.
- [74] Martos MR, Hendry BM, Rodríguez-Puyol M, Dwight J, Díez-Marqués ML, Rodríguez-Puyol D. Haemodialyser biocompatibility and erythrocyte structure and function. *Clin Chim Acta* 1997;265:235-46.
- [75] Costa E, Rocha S, Rocha-Pereira P, Castro E, Miranda V, Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Band 3

profile as a marker of erythrocyte changes in chronic kidney disease patients. *The Open Clinical Chemistry Journal* 2008;1:57-63.

- [76] Costa E, Rocha S, Rocha-Pereira P, Castro E, Miranda V, Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Changes in red blood cells membrane protein composition during haemodialysis procedure. *Ren Fail* 2008;30:971-5.